Investors where fired up Thursday after XenoPort Inc. reported top-line Phase IIb results showing that its gabapentin prodrug significantly reduced neuropathic pain associated with post-herpetic neuralgia (PHN) in adults, driving shares up 25.6 percent. (BioWorld Today)